Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker INCY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thromboc… NCT07623200 · Essential Thrombocythemia INCA033989, Best Available Treatment | INCY Incyte Corporation | Phase 3 | Recruiting | 426 | Jun 15, 2029 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Muta… NCT07522073 · Solid Tumors INCB161734, Placebo | INCY Incyte Corporation | Phase 3 | Recruiting | 588 | Sep 15, 2028 | Registry ↗ |
| Nov 13, 2026 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms NCT07441694 · Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy | INCY Incyte Corporation | Phase 1 | Recruiting | 218 | May 24, 2030 | Registry ↗ |
| Nov 13, 2026 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to… NCT07213973 · Hidradenitis Suppurativa (HS) Povorcitinib | INCY Incyte Corporation | Phase 2 | Recruiting | 40 | Mar 25, 2028 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic… NCT07124078 · Chronic Graft-versus-host-disease INCA034176, Best available Treatment (BAT) | INCY Incyte Corporation | Phase 2 | Recruiting | 60 | Jan 31, 2029 | Registry ↗ |
| Nov 13, 2026 | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib NCT06855498 · Hidradenitis Suppurativa (HS) povorcitinib | INCY Incyte Corporation | Phase 3 | Recruiting | 600 | Feb 28, 2028 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Ho… NCT06585774 · Chronic Graft-versus-host-disease INCA034176, Placebo | INCY Incyte Corporation | Phase 3 | Recruiting | 240 | Sep 28, 2027 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodu… NCT06516965 · Prurigo Nodularis Povorcitinib, Placebo | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 346 | Sep 28, 2026 | Registry ↗ |
| Nov 12, 2026 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Su… NCT06959225 · Hidradenitis Suppurativa Ruxolitinib Cream, Vehicle Cream | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 580 | Oct 29, 2026 | Registry ↗ |
| Nov 9, 2026 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Su… NCT06958211 · Hidradenitis Suppurativa Ruxolitinib Cream, Vehicle Cream | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 573 | Oct 1, 2026 | Registry ↗ |
| Nov 6, 2026 | A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose… NCT07814404 · Healthy Participants INCB161734 | INCY Incyte Corporation | Phase 1 | Completed was active, not recruiting | 10 | Oct 15, 2026 | Registry ↗ |
| Nov 6, 2026 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodul… NCT05764161 · Prurigo Nodularis Ruxolitinib Cream, Vehicle Cream | INCY Incyte Corporation | Phase 3 | Completed | 190 | Dec 30, 2024 | Registry ↗ |
| Nov 5, 2026 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moder… NCT05620836 · Hidradenitis Suppurativa (HS) Povorcitinib, Placebo | INCY Incyte Corporation | Phase 3 | Completed | 619 | Jan 7, 2025 | Registry ↗ |
| Oct 30, 2026 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With o… NCT07284849 · CRC (Colorectal Cancer) INCA33890, Placebo | INCY Incyte Corporation | Phase 3 | Recruiting | 700 | Dec 29, 2028 | Registry ↗ |
| Oct 30, 2026 | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoi… NCT07104565 · Immune Thrombocytopenia INCA000585 | INCY Incyte Corporation | Phase 2 | Recruiting | 56 | Sep 23, 2027 | Registry ↗ |
| Oct 29, 2026 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutan… NCT07448155 · Healthy Participants INCA033989, Bioavailability enhancer | INCY Incyte Corporation | Phase 1 | Active, not recruiting was recruiting | 108 | Nov 14, 2026 | Registry ↗ |
| Oct 22, 2026 | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/M… NCT06615050 · Graft-versus-host Disease (GVHD) Tacrolimus (Tac), Methotrexate (MTX) | INCY Incyte Corporation | Phase 3 | Recruiting | 572 | Jan 17, 2031 | Registry ↗ |
| Oct 22, 2026 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Rel… NCT05429268 · Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Tafasitamab, Lenalidomide | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 82 | Mar 30, 2026 | Registry ↗ |
| Oct 22, 2026 | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia… NCT05090891 · Fibrodysplasia Ossificans Progressiva (FOP) INCB000928, Placebo | INCY Incyte Corporation | Phase 2 | Recruiting | 98 | Jul 30, 2027 | Registry ↗ |
| Oct 20, 2026 | A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic… NCT07862998 · Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholan… Pemigatinib | INCY Incyte Corporation | Phase 2 | Not yet recruiting | 72 | Feb 25, 2031 | Registry ↗ |
| Oct 20, 2026 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma NCT05888844 · Cutaneous Squamous Cell Carcinoma INCB099280 | INCY Incyte Corporation | Phase 2 | Terminated | 63 | Sep 28, 2026 | Registry ↗ |
| Oct 20, 2026 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint I… NCT05879822 · Advanced Solid Tumor INCB099280 | INCY Incyte Corporation | Phase 2 | Terminated | 73 | Sep 30, 2026 | Registry ↗ |
| Oct 15, 2026 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Plat… NCT07214779 · Ovarian Cancer INCB123667, Investigator's choice of chemotherapy | INCY Incyte Corporation | Phase 3 | Recruiting | 466 | Nov 15, 2028 | Registry ↗ |
| Oct 15, 2026 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Partic… NCT06388564 · Chronic Graft-versus-host-disease Axatilimab, Ruxolitinib | INCY Incyte Corporation | Phase 2 | Active, not recruiting | 130 | Oct 1, 2026 | Registry ↗ |
| Oct 15, 2026 | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Ato… NCT06238817 · Atopic Dermatitis Ruxolitinib Cream, Vehicle Cream | INCY Incyte Corporation | Phase 3 | Completed | 241 | May 21, 2025 | Registry ↗ |
| Oct 9, 2026 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Do… NCT07588139 · Healthy Participants Povorcitinib, Ruxolitinib | INCY Incyte Corporation | Phase 1 | Completed | 24 | Sep 8, 2026 | Registry ↗ |
| Oct 9, 2026 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Maligna… NCT07195916 · Solid Tumors, Hematologic Malignancies INCA036873 | INCY Incyte Corporation | Phase 1 | Recruiting | 280 | Aug 18, 2028 | Registry ↗ |
| Oct 9, 2026 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hi… NCT07049575 · Hidradenitis Suppurativa Ruxolitinib Cream | INCY Incyte Corporation | Phase 1 | Recruiting | 24 | Dec 9, 2026 | Registry ↗ |
| Oct 9, 2026 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old)… NCT06804811 · NonSegmental Vitiligo Ruxolitinib Cream, Vehicle Cream | INCY Incyte Corporation | Phase 3 | Recruiting | 250 | Apr 30, 2027 | Registry ↗ |
| Oct 6, 2026 | Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease NCT05919511 · cGVHD Non-Interventional | INCY Incyte Corporation | — | Recruiting | 1,500 | Oct 15, 2027 | Registry ↗ |
| Oct 2, 2026 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Ren… NCT07854249 · Renal Insufficiency, Kidney Diseases INCB161734 | INCY Incyte Corporation | Phase 1 | Not yet recruiting | 24 | Mar 30, 2027 | Registry ↗ |
| Oct 2, 2026 | Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance The… NCT07797283 · Ovarian Cancer INCB123667, Bevacizumab | INCY Incyte Corporation | Phase 3 | Not yet recruiting | 590 | May 1, 2032 | Registry ↗ |
| Oct 1, 2026 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impa… NCT07853040 · Hepatic Insufficiency, Liver Diseases INCB161734 | INCY Incyte Corporation | Phase 1 | Not yet recruiting | 24 | Mar 31, 2027 | Registry ↗ |
| Oct 1, 2026 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With An… NCT04455841 · Anemia, Post-essential Thrombocythemia Myelofibrosis INCB000928, ruxolitinib | INCY Incyte Corporation | Phase 1/2 | Completed | 84 | Apr 1, 2025 | Registry ↗ |
| Sep 29, 2026 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or… NCT03358472 · Head and Neck Cancer Pembrolizumab, Epacadostat | INCY Incyte Corporation | Phase 3 | Completed | 89 | Jul 19, 2018 | Registry ↗ |
| Sep 25, 2026 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metast… NCT04472429 · Squamous Cell Carcinoma of the Anal Canal carboplatin, paclitaxel | INCY Incyte Corporation | Phase 3 | Completed | 308 | Apr 15, 2024 | Registry ↗ |
| Sep 22, 2026 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Micro… NCT07823322 · CRC (Colorectal Cancer) INCA33890 | INCY Incyte Corporation | Phase 2 | Not yet recruiting | 40 | May 14, 2029 | Registry ↗ |
| Sep 15, 2026 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexp… NCT07023627 · Ovarian Cancer INCB123667 | INCY Incyte Corporation | Phase 2 | Recruiting | 160 | Apr 27, 2027 | Registry ↗ |
| Sep 14, 2026 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Non… NCT06548360 · NonSegmental Vitiligo Ruxolitinib Cream, Vehicle Cream | INCY Incyte Corporation | Phase 3 | Recruiting | 180 | Jun 5, 2028 | Registry ↗ |
| Sep 8, 2026 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring… NCT06039384 · Advanced Solid Tumors INCB099280, adagrasib | INCY Incyte Corporation | Phase 1 | Terminated | 6 | Apr 11, 2025 | Registry ↗ |
| Sep 4, 2026 | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compar… NCT04680052 · Follicular Lymphoma, Marginal Zone Lymphoma tafasitamab, rituximab | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 654 | Feb 23, 2024 | Registry ↗ |
| Sep 2, 2026 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors NCT06873789 · Solid Tumors, Advanced Solid Tumors INCB177054, Retifanlimab | INCY Incyte Corporation | Phase 1/2 | Terminated | 9 | Jul 29, 2026 | Registry ↗ |
| Aug 25, 2026 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Ver… NCT06821542 · Chronic Graft-versus-host-disease INCA034176, Best Available Therapy (BAT) | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 9 | May 31, 2028 | Registry ↗ |
| Aug 25, 2026 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G… NCT06818812 · Solid Tumors INCB186748, Cetuximab | INCY Incyte Corporation | Phase 1 | Active, not recruiting | 30 | Mar 27, 2027 | Registry ↗ |
| Aug 25, 2026 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate… NCT06212999 · Hidradenitis Suppurativa (HS) Povorcitinib | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 617 | Dec 26, 2026 | Registry ↗ |
| Aug 25, 2026 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo… NCT06113445 · NonSegmental Vitiligo Povorcitinib, Placebo | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 467 | Feb 24, 2026 | Registry ↗ |
| Aug 19, 2026 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <1… NCT06832618 · Atopic Dermatitis Ruxolitinib, Vehicle Cream | INCY Incyte Corporation | Phase 3 | Active, not recruiting | 159 | Aug 7, 2026 | Registry ↗ |
| Aug 17, 2026 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN0239… NCT04370704 · Melanoma INCAGN02385, INCAGN02390 | INCY Incyte Corporation | Phase 1/2 | Completed | 61 | Aug 25, 2025 | Registry ↗ |
| Aug 17, 2026 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studie… NCT02955940 · Pancreatic Cancer, Colorectal Cancer (CRC) Ruxolitinib, Capecitabine | INCY Incyte Corporation | Phase 2 | Active, not recruiting | 10 | Sep 30, 2027 | Registry ↗ |
| Aug 12, 2026 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative… NCT06313593 · Myeloproliferative Neoplasms INCB160058, Standard disease-directed therapy | INCY Incyte Corporation | Phase 1 | Active, not recruiting | 37 | Oct 9, 2028 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances